Risperidone is an antipsychotic medication that works by interfering with the communication among nerves in the brain. The nerves communicate with one another by producing and releasing chemicals called neurotransmitters. The neurotransmitters attach to receptors on other nearby nerves, and the attachment of the neurotransmitter causes changes in the cells that have the receptor on them. Risperidone blocks several of the receptors on nerves including dopamine type 2, serotonin type 2, and alpha 2 adrenergic receptors and this blocks communication among nerves. Risperidone is a relatively new antipsychotic medication that probably has fewer side effects than many of the older medications.
Risperidone was approved by the United States Food and Drug Administration
(FDA) in 1993 for the treatment of schizophrenia. On Wednesday,
August 22, 2007, Risperdal was approved as the only drug agent available
for treatment of schizophrenia in children ages 13–18; it was also
approved that same day for treatment of bipolar disorder in youths
ages 10–18, joining lithium. Risperidone contains the functional
groups of benzisoxazole and piperidine as part of its molecular
structure. In 2003 the FDA approved risperidone for the short-term
treatment of the mixed and manic states associated with bipolar
disorder. In 2006 the FDA approved risperidone for the treatment
of irritability in children and adolescents with autism. Like other
atypical antipsychotics, it has also been used off-label for the
treatment of anxiety disorders, such as Obsessive-Compulsive disorder;
severe, treatment-resistant depression with or without psychotic
features; Tourette's disorder; disruptive behavior disorders in
children; and eating disorders, among others. A multi-year UK study
by the Alzheimer's Research Trust suggested that this and other
neuroleptic anti-psychotic drugs commonly given to Alzheimer's patients
with mild behavioural problems often make their condition worse.
Risperidone usually is begun as two small doses each day. The doses
often are increased every few days or each week until the optimal
dose is found. Patients who are elderly or have kidney disease may
need lower doses since the kidneys, which are partially responsible
for removing risperidone from the blood, remove risperidone more
slowly, and this can lead to toxic levels of risperidone in the
blood. Similarly, patients with liver disease may need lower doses
since the liver also is partially responsible for removing risperidone.
Buy Risperdal in a Reliable International Online Pharmacy Free International Shipping
Common side effects include akathisia, anxiety, insomnia, low blood
pressure, muscle stiffness, muscle pain, sedation, tremors, increased
salivation, and stuffy nose. Risperidone has been associated with
minimal to moderate weight gain, with one study finding that 26
to 38 percent of participants on the drug experienced weight gain.
It has also been known to cause sexual dysfunction such as retrograde
ejaculation. Occasionally breast tenderness and eventually lactation
in both genders may occur. Many antipsychotics are known to increase
prolactin because they inhibit dopamine. However, risperidone is
known to increase prolactin to a greater extent than most other
antipsychotics, such as quetiapine. It is thought that once risperidone
raises prolactin, it may cause non-cancerous tumors in the pituitary
gland. This may recur even if the patient has switched to a different
antipsychotic. Risperidone can potentially cause tardive dyskinesia
(TD), extrapyramidal symptoms (EPS), and neuroleptic malignant syndrome
(NMS); although the risk of tardive dyskinesia is generally less
than for the older typical antipsychotics[citation needed]. Also,
risperidone can trigger diabetes and more serious conditions of
glucose metabolism, including ketoacidosis and hyperosmolar coma.
There are no adequate studies of risperidone in pregnant women. Some studies in animals suggest no important effects on the fetus, whereas others suggest an ill-effect. Risperidone can be used in pregnancy if the physician feels that the benefits outweigh the potential but unknown risks.
Premarketing experience included eight reports of acute RISPERDAL® overdosage with estimated doses ranging from 20 to 300 mg and no fatalities. In general, reported signs and symptoms were those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness and sedation, tachycardia and hypotension, and extrapyramidal symptoms. One case, involving an estimated overdose of 240 mg, was associated with hyponatremia, hypokalemia, prolonged QT, and widened QRS. Another case, involving an estimated overdose of 36 mg, was associated with a seizure.
Postmarketing experience includes reports of acute RISPERDAL® overdosage, with estimated doses of up to 360 mg. In general, the most frequently reported signs and symptoms are those resulting from an exaggeration of the drug's known pharmacological effects, i.e., drowsiness, sedation, tachycardia, hypotension, and extrapyramidal symptoms. Other adverse reactions reported since market introduction related to RISPERDAL® overdose include prolonged QT intervaland convulsions. Torsade de pointes has been reported in association with combined overdose of RISPERDAL® and paroxetine.
Risperdal is to be used only by the patient for whom it is prescribed. Do not share it with other people.
If your symptoms do not improve or if they become worse, check with your doctor.